Peptides for depression and anxiety: what TikTok gets wrong

What did @healing_mind_body_soul actually say?

Adam told his audience he "just came across" a peptide called PE-22-28 and described it as "a very fast acting anti-depressant" that "binds to the Trek 1 receptor." His central claim is that blocking that receptor means you "will not" be able to become depressed. He pointed viewers to Google and Reddit for research, and his caption encouraged talking to a doctor. That last part is reasonable advice. Everything before it deserves a closer look.

To be fair, Adam is not selling anything in this clip, and he does not prescribe a dose or claim PE-22-28 cures depression. He is clearly enthusiastic, but the framing, specifically the word "literally" applied to mouse model results, is where the trouble starts. Translating rodent neuroscience into human mental health outcomes is one of the most reliably difficult problems in psychiatry research.

Does the science back this up?

There is real, peer-reviewed research behind PE-22-28, but it is early-stage animal data, not human evidence. The excitement is not invented, but it is being applied well beyond what the studies actually demonstrate.

PE-22-28 is a synthetic analog of spadin, a peptide derived from the sortilin propeptide. Researchers identified it as a TREK-1 channel blocker with antidepressant-like effects in rodent models. The foundational work comes from Djillani et al. (2017, Frontiers in Pharmacology), who showed that spadin and its analogs produced antidepressant-like behavior in mice using forced swim and tail suspension tests. A follow-up study by the same group (Djillani et al., 2018, Frontiers in Physiology) found PE-22-28 outperformed spadin in terms of potency and duration of effect in those same mouse models.

Here is the problem: forced swim tests in mice are not depression. They measure behavioral despair, which correlates loosely with depressive-like states, but the translational record from this model to human antidepressant efficacy is, charitably, mixed. No published human clinical trial data for PE-22-28 exists as of mid-2025. There is no Phase I safety data in people. We do not know the effective dose, the side effect profile, or whether it crosses the human blood-brain barrier reliably enough to do anything at all.

What did they get wrong (or right)?

Adam got the receptor right. TREK-1, a two-pore domain potassium channel, is a legitimate target in depression research. Heurteaux et al. (2006, Nature Neuroscience) showed that TREK-1 knockout mice display antidepressant-like phenotypes, which is what set this whole line of inquiry in motion. That foundational piece of neuroscience is solid.

What he got wrong is the leap from mouse data to human application. Saying that blocking TREK-1 means you "literally" cannot become depressed overstates the science by a significant margin. Depression is not a single receptor problem. It involves serotonergic, dopaminergic, GABAergic, and glutamatergic systems, plus HPA axis dysfunction, neuroinflammation, and structural brain changes. No single receptor block prevents it.

He also describes this as something he "just came across," framing novelty as a selling point. In drug development, novelty without human data is a risk factor, not a feature. Dozens of antidepressant candidates that looked extraordinary in rodents have failed in human trials.

What should you actually know?

PE-22-28 is a research compound. That category is meaningful. It means it has not been evaluated for human safety or efficacy by any regulatory body. If you find it being sold online, it is being sold for research purposes only, and anyone marketing it as a human antidepressant is operating outside what the evidence currently supports.

If you have depression or anxiety, this is not a replacement for established treatments. SSRIs, SNRIs, psychotherapy, and in appropriate cases, ketamine-based treatments, have actual human clinical trial data behind them. That data is imperfect and incomplete, but it exists. PE-22-28's human data does not yet exist.

TREK-1 antagonism is a genuinely interesting avenue of research. If larger studies pan out, this could eventually matter. But "could eventually matter" is a long way from "take this for depression." Anyone sourcing unregulated peptides from gray-market suppliers is also taking on unknown purity and contamination risks that have nothing to do with the underlying pharmacology.

• Talk to a licensed clinician before pursuing any peptide therapy, including ones with plausible mechanisms.
• Reddit is not a substitute for clinical evidence. Neither is Google.
• Being interested in the science is fine. Treating mouse-model results as a protocol is not.